| 1 |
35284671 | Iduronate-2-sulfatase interactome: validation by yeast two-hybrid assay. | 2022 Mar |
2 |
| 2 |
34622797 | Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. | 2021 Oct 8 |
2 |
| 3 |
32631737 | Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy. | 2020 Aug |
1 |
| 4 |
32751752 | High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II. | 2020 Jul 30 |
2 |
| 5 |
31193135 | Identification of the iduronate-2-sulfatase proteome in wild-type mouse brain. | 2019 May |
2 |
| 6 |
29606503 | A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. | 2018 May 2 |
1 |
| 7 |
29978271 | The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology. | 2018 Nov |
2 |
| 8 |
30064964 | Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS. | 2018 Sep |
1 |
| 9 |
28478695 | Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer. | 2017 Aug |
1 |
| 10 |
27699273 | CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). | 2016 Jun 16 |
2 |
| 11 |
25761450 | Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II. | 2015 Jun |
1 |
| 12 |
23529876 | Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice. | 2013 May |
2 |
| 13 |
22279584 | CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. | 2012 |
1 |
| 14 |
22704483 | Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. | 2012 Sep |
1 |
| 15 |
21319344 | Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation. | 2011 Mar |
1 |
| 16 |
17459751 | Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. | 2007 Jun |
4 |
| 17 |
15966019 | Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. | 2005 Nov |
4 |
| 18 |
8325651 | Cloning and characterization of the cDNA for the murine iduronate sulfatase gene. | 1993 Jun |
1 |